X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (22583) 22583
Book Review (3048) 3048
Publication (1942) 1942
Book Chapter (64) 64
Conference Proceeding (47) 47
Magazine Article (17) 17
Dissertation (16) 16
Government Document (14) 14
Book / eBook (5) 5
Newsletter (3) 3
Newspaper Article (3) 3
Data Set (2) 2
Paper (2) 2
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20705) 20705
humans (19788) 19788
female (15259) 15259
oncology (11346) 11346
breast cancer (9122) 9122
middle aged (8046) 8046
receptor, erbb-2 - metabolism (7647) 7647
breast neoplasms - pathology (7193) 7193
adult (6496) 6496
cancer (6473) 6473
aged (6453) 6453
prognosis (5499) 5499
breast neoplasms - metabolism (5147) 5147
immunohistochemistry (4924) 4924
breast neoplasms - drug therapy (4494) 4494
animals (4481) 4481
receptor, erbb-2 - genetics (4478) 4478
expression (4027) 4027
breast neoplasms - genetics (3987) 3987
trastuzumab (3662) 3662
tumors (3419) 3419
receptor, erbb-2 - analysis (3317) 3317
chemotherapy (3227) 3227
research (3112) 3112
aged, 80 and over (3099) 3099
male (3063) 3063
cell line, tumor (2990) 2990
mice (2847) 2847
her2 (2711) 2711
survival (2672) 2672
epidermal growth factor (2648) 2648
analysis (2631) 2631
pathology (2568) 2568
metastasis (2517) 2517
gene expression (2503) 2503
carcinoma (2479) 2479
neoplasm staging (2466) 2466
receptors, estrogen - metabolism (2459) 2459
care and treatment (2448) 2448
medicine & public health (2377) 2377
erbb-2 protein (2293) 2293
therapy (2287) 2287
gene expression regulation, neoplastic (2099) 2099
cell biology (2083) 2083
growth-factor receptor (2038) 2038
treatment outcome (2035) 2035
breast-cancer (2027) 2027
receptors, progesterone - metabolism (1981) 1981
genetic aspects (1972) 1972
antineoplastic agents - therapeutic use (1968) 1968
gene amplification (1963) 1963
breast neoplasms - mortality (1947) 1947
biomarkers, tumor - analysis (1930) 1930
retrospective studies (1914) 1914
health aspects (1903) 1903
antineoplastic combined chemotherapy protocols - therapeutic use (1899) 1899
signal transduction (1899) 1899
proteins (1879) 1879
skin and connective tissue diseases (1834) 1834
biochemistry & molecular biology (1791) 1791
disease-free survival (1786) 1786
biomarkers, tumor - metabolism (1758) 1758
research article (1643) 1643
breast neoplasms - chemistry (1634) 1634
estrogen (1614) 1614
cells (1491) 1491
medicine (1471) 1471
amplification (1455) 1455
receptor, erbb-2 - biosynthesis (1432) 1432
receptor, epidermal growth factor - metabolism (1425) 1425
mutation (1412) 1412
overexpression (1405) 1405
receptor (1405) 1405
receptors, estrogen - analysis (1402) 1402
surgery (1400) 1400
survival analysis (1397) 1397
article (1384) 1384
apoptosis (1379) 1379
phosphorylation (1365) 1365
kinases (1356) 1356
cancer research (1338) 1338
estrogen-receptor (1316) 1316
receptor, erbb-2 - antagonists & inhibitors (1311) 1311
lymphatic metastasis (1307) 1307
risk factors (1273) 1273
abridged index medicus (1253) 1253
survival rate (1247) 1247
antibodies, monoclonal, humanized (1237) 1237
development and progression (1223) 1223
cancer therapies (1210) 1210
antineoplastic agents - pharmacology (1194) 1194
breast neoplasms - diagnosis (1192) 1192
in situ hybridization, fluorescence (1191) 1191
breast (1181) 1181
neoplasm metastasis (1158) 1158
monoclonal-antibody (1145) 1145
receptor, erbb-2 (1125) 1125
multidisciplinary sciences (1124) 1124
medical prognosis (1121) 1121
follow-up studies (1111) 1111
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21989) 21989
Chinese (212) 212
Japanese (152) 152
French (77) 77
German (58) 58
Russian (40) 40
Spanish (33) 33
Hungarian (24) 24
Italian (16) 16
Czech (14) 14
Portuguese (13) 13
Korean (10) 10
Polish (5) 5
Serbian (4) 4
Hebrew (3) 3
Romanian (2) 2
Swedish (2) 2
Dutch (1) 1
Lithuanian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 134 - 141
A multicenter single-group trial suggests that adjuvant therapy with paclitaxel plus trastuzumab lowers the risk of relapse in women with small HER2-positive... 
OVEREXPRESSION | WOMEN | MEDICINE, GENERAL & INTERNAL | ONCOGENE | EFFICACY | SAFETY | RISK | MONOCLONAL-ANTIBODY | CHEMOTHERAPY | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - therapy | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Mastectomy, Segmental | Aged, 80 and over | Adult | Female | Receptor, ErbB-2 - immunology | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Antibodies, Monoclonal, Humanized - adverse effects | Neoplasm Recurrence, Local | Paclitaxel - adverse effects | Survival Rate | Radiotherapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma - mortality | Breast cancer | Dosage and administration | Drug therapy | Risk factors | Paclitaxel | Invasiveness | Clinical trials | Congestive heart failure | Neuropathy | Cancer therapies | Survival | Patients | ErbB-2 protein | Metastases | Chemotherapy | Epidermal growth factor | Ventricle | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Pancreas, ISSN 0885-3177, 03/2013, Volume 42, Issue 2, pp. 216 - 222
Objectives: The objective of this study was to evaluate genetic alterations of K-ras, p53, c-erbB-2, and deleted in pancreatic cancer, locus 4 (DPC4) genes in... 
c-erbB-2 genes | k-ras genes | pancreas | p53 genes | CANCER SURVIVAL | PROTEIN | PAPILLARY-MUCINOUS NEOPLASM | INTRAEPITHELIAL NEOPLASIA | LESIONS | OVEREXPRESSION | CODON-12 MUTATIONS | PROGNOSTIC-SIGNIFICANCE | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | CARCINOMA | Immunohistochemistry | Multivariate Analysis | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Male | Carcinoma, Pancreatic Ductal - surgery | Tumor Suppressor Protein p53 - genetics | Carcinoma, Pancreatic Ductal - genetics | Young Adult | Tumor Suppressor Protein p53 - analysis | Smad4 Protein - genetics | Time Factors | DNA Mutational Analysis | Polymerase Chain Reaction | Adult | Carcinoma, Pancreatic Ductal - mortality | Female | Pancreatic Neoplasms - mortality | Retrospective Studies | CA-19-9 Antigen - blood | Odds Ratio | Republic of Korea - epidemiology | Pancreatic Neoplasms - blood | Genetic Predisposition to Disease | Risk Assessment | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - surgery | Risk Factors | Kaplan-Meier Estimate | Pancreatic Neoplasms - enzymology | Proportional Hazards Models | Pancreatic Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Carcinoma, Pancreatic Ductal - pathology | Biomarkers, Tumor - blood | Carcinoma, Pancreatic Ductal - blood | Carcinoma, Pancreatic Ductal - enzymology | Phenotype | Aged | Biomarkers, Tumor - genetics | Mutation | Receptor, ErbB-2 - analysis | Smad4 Protein - analysis | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | Index Medicus | Abridged Index Medicus | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 19, pp. 1783 - 1791
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to... 
CAPECITABINE | LAPATINIB | MEDICINE, GENERAL & INTERNAL | THERAPY | PHASE-II | ANTIBODY | RECEPTOR | PLUS | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Trastuzumab | Drugs | Dose-response relationship (Biochemistry) | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Comparative analysis | Thrombocytopenia | Chemotherapy | Epidermal growth factor | Vomiting | Diarrhea | Cytotoxicity | Nausea | Survival | ErbB-2 protein | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 209 - 219
In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with... 
TARGET | MEDICINE, GENERAL & INTERNAL | THERAPY | FULVESTRANT | CLINICAL-TRIALS | CYCLIN D | RESISTANCE | MUTATIONS | COMBINATION | ESTROGEN-RECEPTOR | 4/6 INHIBITOR PALBOCICLIB | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Protein Kinase Inhibitors - adverse effects | Receptors, Progesterone - analysis | Pyridines - adverse effects | Aged, 80 and over | Estradiol - adverse effects | Adult | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - therapeutic use | Double-Blind Method | Estradiol - therapeutic use | Biomarkers - analysis | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Receptor, ErbB-2 - analysis | Women | Hormone receptors | Care and treatment | Usage | Breast cancer | Diagnosis | Health aspects | Thrombocytopenia | Leukopenia | Endocrine therapy | Fatigue | Metastasis | Cancer therapies | Cyclin-dependent kinase 4 | Fulvestrant | Metastases | Epidermal growth factor | Womens health | S phase | Cell cycle | Neutropenia | G1 phase | Index Medicus | Abridged Index Medicus
Journal Article